Shortage of Dopamine Hydrochloride Injection in the US
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage for specific presentations of Dopamine Hydrochloride Injection, a cardiovascular drug, with one manufacturer facing delays.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dopamine Hydrochloride Injection.
Shortage of Dopamine Hydrochloride Injection
What's in Shortage
The generic drug Dopamine Hydrochloride Injection, with brand names DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE AND DEXTROSE, and DOPAMINE HYDROCHLORIDE IN DEXTROSE, is in a current shortage status. It is available as an injection in the cardiovascular therapeutic category. The shortage was first posted on 11/06/2017 and last updated on 03/27/2026.
Which Manufacturers Are Affected
Several manufacturers are involved in supplying Dopamine Hydrochloride Injection:
- Hospira, Inc., a Pfizer Company: Available for presentations such as Dopamine Hydrochloride Injection 400 mg/10mL and 200 mg/5mL, as well as certain Dopamine Hydrochloride In Dextrose 5% options. However, it is unavailable for Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL), with next delivery estimated for December 2027 due to manufacturing delay. Contact: 844-646-4398.
- Baxter Healthcare: Available for presentations such as Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL and 160 mg/100 mL. Contact: 888-229-0001.
Why There's a Shortage
For the unavailable presentation from Hospira, Inc., the reason is a manufacturing delay. No specific reasons were provided for other manufacturers.
What Patients Should Do
Patients who depend on this medication should talk to their pharmacist or healthcare provider to check on availability and discuss next steps. They can also contact the manufacturers for more information. Please note that patients should always consult their healthcare provider and not make any changes without professional advice.
Source
This information is attributed to the FDA Drug Shortages Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,767 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.